| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Xeris Biopharma Holdings (NASDAQ:XERS) through any online brokerage.
Other companies in Xeris Biopharma Holdings’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Xeris Biopharma Holdings has a consensus price target of $11.38.
The stock price for Xeris Biopharma Holdings (NASDAQ: XERS) is $10.29 last updated October 16, 2026 at 7:25 PM EDT.
There are no upcoming dividends for Xeris Biopharma Holdings.
Xeris Biopharma Holdings does not have any upcoming earnings scheduled.
There is no upcoming split for Xeris Biopharma Holdings.
Xeris Biopharma Holdings is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
